TY - JOUR
T1 - Safety considerations when using non-ergot dopamine agonists to treat Parkinson’s disease
AU - Stocchi, Fabrizio
AU - Fossati, Barbara
AU - Torti, Margherita
N1 - Funding Information:
This paper was not funded.
Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Introduction: Nonergot dopamine agonists (NEDA) represent an excellent treatment option for Parkinson’s disease (PD) patients, in both early and advanced stages of the disease. The post-marketing phase of NEDA has highlighted, though, the occurrence of important long-term adverse events. Areas covered: This review reports recent updates on NEDA adverse events, analyzing neurobiological bases and risk factors of these complications. A literature search has been performed using Medline and reviewing the bibliographies of selected articles. Expert opinion: NEDA represents a very important option in the treatment of PD. Criticisms on their use can be overcome through a better knowledge of these molecules and of the risk factors for adverse events which allow specialists to prevent the occurrence of undesired complications and consent a tailor-based approach. Abbreviations: PD: Parkinson’s disease, DA: dopamine agonists, NEDA: non-ergot dopamine agonists, ICD: impulse control disorders, DAWS: dopamine agonist withdrawal syndrome, CYP: Cytochrome P, PK: pharmacokinetic, AUC: area under the curve, HRT: hormone replacement therapy, AV: atrioventricular, HF: heart failure, OH: orthostatic hypotension, RBD: REM behavior disorders, PDP: Parkinson’s disease psychosis, DRT: dopamine replacement therapy, DDS: dopamine dysregulation syndrome, MMSE: Mini-Mental state examination, EDS: excessive daytime somnolence.
AB - Introduction: Nonergot dopamine agonists (NEDA) represent an excellent treatment option for Parkinson’s disease (PD) patients, in both early and advanced stages of the disease. The post-marketing phase of NEDA has highlighted, though, the occurrence of important long-term adverse events. Areas covered: This review reports recent updates on NEDA adverse events, analyzing neurobiological bases and risk factors of these complications. A literature search has been performed using Medline and reviewing the bibliographies of selected articles. Expert opinion: NEDA represents a very important option in the treatment of PD. Criticisms on their use can be overcome through a better knowledge of these molecules and of the risk factors for adverse events which allow specialists to prevent the occurrence of undesired complications and consent a tailor-based approach. Abbreviations: PD: Parkinson’s disease, DA: dopamine agonists, NEDA: non-ergot dopamine agonists, ICD: impulse control disorders, DAWS: dopamine agonist withdrawal syndrome, CYP: Cytochrome P, PK: pharmacokinetic, AUC: area under the curve, HRT: hormone replacement therapy, AV: atrioventricular, HF: heart failure, OH: orthostatic hypotension, RBD: REM behavior disorders, PDP: Parkinson’s disease psychosis, DRT: dopamine replacement therapy, DDS: dopamine dysregulation syndrome, MMSE: Mini-Mental state examination, EDS: excessive daytime somnolence.
KW - Dopamine agonists
KW - heart failure
KW - impulse control disorders
KW - non ergot derivatives
KW - parkinson’s disease
KW - safety
KW - safety3
KW - side effects
UR - http://www.scopus.com/inward/record.url?scp=85092098057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092098057&partnerID=8YFLogxK
U2 - 10.1080/14740338.2020.1804550
DO - 10.1080/14740338.2020.1804550
M3 - Review article
C2 - 32869676
AN - SCOPUS:85092098057
VL - 19
SP - 1155
EP - 1172
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
SN - 1474-0338
IS - 9
ER -